GB0113233D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0113233D0
GB0113233D0 GBGB0113233.1A GB0113233A GB0113233D0 GB 0113233 D0 GB0113233 D0 GB 0113233D0 GB 0113233 A GB0113233 A GB 0113233A GB 0113233 D0 GB0113233 D0 GB 0113233D0
Authority
GB
United Kingdom
Prior art keywords
halogen
optionally substituted
alkyl
6alkyl
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0113233.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0113233.1A priority Critical patent/GB0113233D0/en
Publication of GB0113233D0 publication Critical patent/GB0113233D0/en
Priority to PCT/EP2002/005885 priority patent/WO2002096894A1/en
Priority to HU0400056A priority patent/HUP0400056A2/hu
Priority to JP2003500073A priority patent/JP2004532266A/ja
Priority to US10/478,259 priority patent/US6867225B2/en
Priority to AU2002312954A priority patent/AU2002312954B2/en
Priority to KR10-2003-7015688A priority patent/KR20040007633A/ko
Priority to EP02738123A priority patent/EP1392665B1/en
Priority to AT02738123T priority patent/ATE377007T1/de
Priority to ES02738123T priority patent/ES2295352T3/es
Priority to CZ20033250A priority patent/CZ20033250A3/cs
Priority to IL15881802A priority patent/IL158818A0/xx
Priority to CNA028110803A priority patent/CN1529698A/zh
Priority to PL02367215A priority patent/PL367215A1/xx
Priority to BR0210077-0A priority patent/BR0210077A/pt
Priority to CA002448103A priority patent/CA2448103A1/en
Priority to MXPA03010584A priority patent/MXPA03010584A/es
Priority to DE60223245T priority patent/DE60223245T2/de
Priority to ZA200308864A priority patent/ZA200308864B/en
Priority to NO20035316A priority patent/NO20035316D0/no
Priority to CO03106071A priority patent/CO5540299A2/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0113233.1A 2001-05-31 2001-05-31 Chemical compounds Ceased GB0113233D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB0113233.1A GB0113233D0 (en) 2001-05-31 2001-05-31 Chemical compounds
DE60223245T DE60223245T2 (de) 2001-05-31 2002-05-29 Thiazol- und oxazolderivate, die sich für die behandlung von herzkreislauferkrankungen und ähnlichen erkrankungen eignen
CZ20033250A CZ20033250A3 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
CNA028110803A CN1529698A (zh) 2001-05-31 2002-05-29 用于治疗心血管及有关疾病的噻唑或噁唑衍生物
JP2003500073A JP2004532266A (ja) 2001-05-31 2002-05-29 心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体
US10/478,259 US6867225B2 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
AU2002312954A AU2002312954B2 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
KR10-2003-7015688A KR20040007633A (ko) 2001-05-31 2002-05-29 심혈관 질환 및 이와 관련된 질환의 치료에 유용한 티아졸또는 옥사졸 유도체
EP02738123A EP1392665B1 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
AT02738123T ATE377007T1 (de) 2001-05-31 2002-05-29 Thiazol- und oxazolderivate, die sich für die behandlung von herzkreislauferkrankungen und ähnlichen erkrankungen eignen
ES02738123T ES2295352T3 (es) 2001-05-31 2002-05-29 Derivados de tiazol o de oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas con las mismas.
PCT/EP2002/005885 WO2002096894A1 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
IL15881802A IL158818A0 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
HU0400056A HUP0400056A2 (hu) 2001-05-31 2002-05-29 Tiazol- vagy oxazolszármazékok, melyek szív-érrendszeri betegségek gyógyítására alkalmazhatók és a vegyületeket tartalmazó gyógyszerkészítmények
PL02367215A PL367215A1 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
BR0210077-0A BR0210077A (pt) 2001-05-31 2002-05-29 Composto, seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa
CA002448103A CA2448103A1 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
MXPA03010584A MXPA03010584A (es) 2001-05-31 2002-05-29 Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas.
ZA200308864A ZA200308864B (en) 2001-05-31 2003-11-13 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases.
NO20035316A NO20035316D0 (no) 2001-05-31 2003-11-28 Tiazol- eller oksazol-derivater som er anvendelige ved behandling av kardiovaskul¶re og beslektede sykdommer
CO03106071A CO5540299A2 (es) 2001-05-31 2003-12-02 Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0113233.1A GB0113233D0 (en) 2001-05-31 2001-05-31 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0113233D0 true GB0113233D0 (en) 2001-07-25

Family

ID=9915638

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0113233.1A Ceased GB0113233D0 (en) 2001-05-31 2001-05-31 Chemical compounds

Country Status (21)

Country Link
US (1) US6867225B2 (https=)
EP (1) EP1392665B1 (https=)
JP (1) JP2004532266A (https=)
KR (1) KR20040007633A (https=)
CN (1) CN1529698A (https=)
AT (1) ATE377007T1 (https=)
AU (1) AU2002312954B2 (https=)
BR (1) BR0210077A (https=)
CA (1) CA2448103A1 (https=)
CO (1) CO5540299A2 (https=)
CZ (1) CZ20033250A3 (https=)
DE (1) DE60223245T2 (https=)
ES (1) ES2295352T3 (https=)
GB (1) GB0113233D0 (https=)
HU (1) HUP0400056A2 (https=)
IL (1) IL158818A0 (https=)
MX (1) MXPA03010584A (https=)
NO (1) NO20035316D0 (https=)
PL (1) PL367215A1 (https=)
WO (1) WO2002096894A1 (https=)
ZA (1) ZA200308864B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
AU2003261935A1 (en) 2002-09-06 2004-03-29 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
FR2901792A1 (fr) * 2006-06-06 2007-12-07 Negma Lerads Soc Par Actions S DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CA2744985C (en) 2008-12-01 2014-05-06 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring useful for the prevention or treatment of hyperlipidemia
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6207422B1 (en) * 1998-04-17 2001-03-27 The Metrohealth System Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same
WO2000018903A2 (en) * 1998-09-29 2000-04-06 The Johns Hopkins University Inducible genetic suppression of cellular excitability
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US7091225B2 (en) 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists

Also Published As

Publication number Publication date
ZA200308864B (en) 2005-02-14
CZ20033250A3 (en) 2004-03-17
JP2004532266A (ja) 2004-10-21
ES2295352T3 (es) 2008-04-16
NO20035316L (no) 2003-11-28
DE60223245D1 (de) 2007-12-13
BR0210077A (pt) 2004-06-22
AU2002312954B2 (en) 2004-12-02
PL367215A1 (en) 2005-02-21
US20040176427A1 (en) 2004-09-09
HUP0400056A2 (hu) 2004-04-28
ATE377007T1 (de) 2007-11-15
US6867225B2 (en) 2005-03-15
NO20035316D0 (no) 2003-11-28
WO2002096894A1 (en) 2002-12-05
CN1529698A (zh) 2004-09-15
EP1392665A1 (en) 2004-03-03
DE60223245T2 (de) 2008-08-14
CA2448103A1 (en) 2002-12-05
MXPA03010584A (es) 2004-03-09
IL158818A0 (en) 2004-05-12
EP1392665B1 (en) 2007-10-31
CO5540299A2 (es) 2005-07-29
KR20040007633A (ko) 2004-01-24

Similar Documents

Publication Publication Date Title
GB0113233D0 (en) Chemical compounds
NO20033848L (no) Nitrogenholdige heteroarylforbindelser med en HIV integrase inhiberende aktivitet
IL159607A0 (en) 7-amino triazolopyrimidines for controlling harmful fungi
CY1107206T1 (el) Παραγωγα οξαζολιου/θειαζολιου ενεργοποιητες του υποδοχεα hppar-a
IL147651A0 (en) Isoxazoline derivative and herbicide containing the same as the active ingredient
DK1323710T3 (da) Nitrogenholdige femleddede ringforbindelser
ATE368655T1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
WO2003055441A3 (en) Medicaments
DK1447400T3 (da) Bicyklisk forbindelse
FI953710A0 (fi) Uusia pyrrolokarbatsoleja
EA200501136A1 (ru) Триазольные соединения, полезные в терапии
EP1364945A4 (en) BENZIMIDAZOLIDINONDERIVATE
ATE273981T1 (de) Fungiizide 6-(trifluormethyl-phenyl)- triazolpyrimidine
GB0003257D0 (en) Heterocyclic compounds and their therapeutic use
MXPA04000371A (es) 6- (2-tolil) - triazolopirimidinas substituidas.
DK1161424T3 (da) Hidtil ukendte diazolderivater som serotonerge midler
HK1042288A1 (zh) 6-[[(芳基和雜芳基)氧]甲基]-萘基-2-甲亞胺酸酰胺衍生物，其製備方法及其在治療方面的應用
GB0116966D0 (en) Anittumoral compounds
TW200503733A (en) T-shaped channel blockers
FI922449A0 (fi) Azetidinonderivat, anvaendbara vid framstaellningen av karbapenemantibiotika.
EP1391450A4 (en) N- (HETEROCYCLYLMETHYL) ALKYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND BACTERICIDE

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)